New cholesterol drug ALN-ANG3 enters early human safety trial
NCT ID NCT06452771
First seen Nov 20, 2025 · Last updated May 24, 2026 · Updated 24 times
Summary
This study tests an experimental drug called ALN-ANG3 in healthy adults with high cholesterol or triglycerides. The main goal is to check if the drug is safe and tolerable, and to see how it moves through the body. About 59 participants will receive either the drug or a placebo. This is an early-phase trial, so it focuses on safety rather than effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS WITH HYPERLIPIDEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
New Zealand Clinical Research
Christchurch, Canterbury, 8013, New Zealand
Conditions
Explore the condition pages connected to this study.